soul trial oral semaglutide trial: 14 mg demonstrated superior reduction in risk of CV events The SOUL Study - by

Only a minority of participants chose to discontinue treatment because of hypersensitivity, and discontinuation rates for these reactions were not significantly higher than those observed with placebo groups

Rodier, Y

If passed, TROA would: Permanently allow Medicare Part D to cover FDA-approved anti-obesity medications Expand Medicare Part B coverage of intensive behavioral therapy for obesity to include a wider range of providers (not just primary care physicians) However, in April 2025, CMS announced it would not include Medicare Part D coverage of obesity drugs in its rule changes for 2026, stating the proposal was "not appropriate at this time." That decision pushed the issue back to Congress, where the TROA remains under consideration

DOI: 10.1073/pnas.1720833115

Expert Opinion on Pharmacotherapy, 24 (6), 791-805

Ferritinophagy/ferroptosis: Iron-related newcomers in human diseases